1801.HK - Innovent Biologics, Inc.

HKSE - HKSE Delayed Price. Currency in HKD
26.850
-0.150 (-0.56%)
At close: 4:08PM HKT
Stock chart is not supported by your current browser
Previous Close27.000
Open27.300
Bid26.700 x 0
Ask26.850 x 0
Day's Range26.600 - 27.500
52 Week Range18.800 - 31.850
Volume2168893
Avg. Volume7,021,936
Market Cap34B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting

    Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced that the latest clinical data of Fully-human BCMA CAR-T, a potential best-in-class cell therapy co-developed with IASO Biotherapeutics (IASO BIO) (Innovent:IBI326, IASO BIO: CT103A), has been presented in an oral session at the prestigious 61st Annual American Society of Hematology (ASH) Meeting & Exposition convened in Orlando, FL, from 7 December 2019 to 10 December 2019 [Abstract 582]. The oral presentation title is "Efficacy and Safety of Fully Human BCMA Targeting CAR T Cell Therapy in Relapsed Refractory Multiple Myeloma".

  • PR Newswire

    Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-LAG-3 Monoclonal Antibody in China

    Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced that the first patient has been successfully dosed in a Phase I clinical trial (CIBI110A101) of anti-lymphocyte activation gene 3 (LAG-3)recombinant fully human monoclonal antibody drug candidate (IBI110) in China.

  • PR Newswire

    Innovent Presents Co-developed Cancer-Fighting Tyvyt(R) (Sintilimab Injection) at CIIE 2019 with Eli Lilly

    Innovent Biologics (01801.HK), a multinational biopharmaceutical company, and Eli Lilly and Company presented their co-developed Tyvyt® (generic name: sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody at CIIE 2019. The medicine works to block the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently help patients restore the endogenous anti-tumour T-cell response. The new medical breakthrough, the result of the cooperation between the two companies, provides global patients with a more effective, safer treatment solution to fight cancer.

  • PR Newswire

    Innovent Biologics Announces FDA Acceptance of NDA for Pemigatinib in Patients with Previously Treated, Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

    Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today announced that the new drug application ("NDA") submitted by Incyte to the U.S. Food and Drug Administration ("FDA") for pemigatinib in previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements has been accepted for Priority Review by FDA.

  • PR Newswire

    Tyvyt (Sintilimab Injection), an Innovative PD-1 Inhibitor Jointly Developed by Innovent and Lilly, is Included in the New Catalogue of National Reimbursement Drug List (NRDL)

    Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced with Eli Lilly and Company ("Lilly") that the innovative PD-1 inhibitor Tyvyt® (sintilimab injection), co-developed by both companies, is the only PD-1 inhibitor that has been included in the new Catalogue of National Reimbursement Drug List ("NRDL") according to the latest announcement from the National Healthcare Security Administration ("NHSA"). (Details of medical insurance reimbursement and other relevant information shall be subject to the information publicized by the Chinese government.)

  • PR Newswire

    Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-PD-1/HER2 Bispecific Antibody in China

    Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today jointly announced with Beijing Hanmi Pharmaceutical Co., Ltd. (a subsidiary of Hanmi Pharmaceutical Co., Ltd.) ("Hanmi") that the first patient has been successfully dosed in a Phase I clinical trial (CIBI315A101) of a recombinant fully human bispecific antibody targeting programmed cell death receptor-1 (PD-1) and human epidermal growth factor receptor 2 (HER2) (IBI315), an innovative antibody co-developed by both companies.

  • Update: Innovent Biologics (HKG:1801) Stock Gained 33% In The Last Year
    Simply Wall St.

    Update: Innovent Biologics (HKG:1801) Stock Gained 33% In The Last Year

    If you want to compound wealth in the stock market, you can do so by buying an index fund. But one can do better than...

  • PR Newswire

    Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma

    SUZHOU, China , Oct. 20, 2019 /PRNewswire/ --  Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes ...

  • PR Newswire

    Innovent and Chi-Med Expand Global Collaboration to Evaluate the Combination of Sintilimab and Surufatinib in Solid Tumors

    SUZHOU, China and LONDON, Oct. 10, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX:01801) and Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announced the expansion of their global collaboration agreement to evaluate the safety and efficacy of Innovent's Tyvyt® (sintilimab injection), a fully human anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody, in combination with Chi-Med's surufatinib, a novel inhibitor of vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor 1 (FGFR1) and colony stimulating factor-1 receptor (CSF-1R), in patients with advanced solid tumors. The expansion of the global collaboration will allow Innovent and Chi-Med to jointly explore the potential application of Tyvyt® and surufatinib combination therapy in solid tumors with global unmet medical needs.

  • PR Newswire

    Innovent Biologics Announces a New Placement Raised HK$2,351.33 Million

    SUZHOU, China, Oct. 4, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX:01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announced today that it has agreed to place 97,000,000 new shares (the "Placing and Subscription Shares") at HK$24.60 (the "Placing and Subscription Price") with overwhelming subscription from well-known international and local investors.

  • NMPA Approves IND Application for CT103A, a Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Biologics
    Business Wire

    NMPA Approves IND Application for CT103A, a Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Biologics

    IASO Biotherapeutics , a clinical stage biotechnology company advancing the development of innovative therapies for cancer, and Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops and commercializes high quality medicines, announced today that IASO BIO has received National Medical Products Administration approval for an Investigational New Drug Application for CT103A—an ...

  • PR Newswire

    Innovent Provides Update on Two Studies of IBI301 (Rituximab Biosimilar) in the Treatment of CD20-positive Lymphoma at Annual Meeting of CSCO

    SUZHOU, China, Sept. 20, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX:01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, metabolic and other major diseases, announced today that the data for two studies of IBI301, a rituximab biosimilar co-developed with Eli Lilly and Company, was presented at the 22nd Annual Meeting of Chinese Society of Clinical Oncology (CSCO). The two clinical trials are CTR20160770 and CTR20160493. CTR20160770 is a multicenter, randomized, double-blind, parallel-controlled trial for pharmacokinetics and safety of recombinant chimeric murine/human anti-CD20 monoclonal antibody (IBI301) in comparison with rituximab in patients with CD20-positive B-cell lymphoma.

  • PR Newswire

    Innovent Provides Update on the Results of IBI305 for the First-line Treatment of Advanced Non-squamous Cell Lung Cancer by Oral Presentation at CSCO

    SUZHOU, China, Sept. 19, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX:01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, metabolic and other major diseases, announced today that the results of efficacy and safety of IBI305 (bevacizumab biosimilar) versus bevacizumab, both in combination with paclitaxel/carboplatin for the first-line treatment of advanced non-small cell lung cancer (NSCLC) patients in a randomized, double-blind Phase III clinical trial (CTR20160848), were presented in an oral session at the 22nd Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) [Thursday, September 19, 11:25 AM -11:30 AM BJT]. 450 patients were enrolled and randomized into IBI305 group (n = 224) and reference bevacizumab (RBv) group (n = 226).

  • Is Innovent Biologics (HKG:1801) Weighed On By Its Debt Load?
    Simply Wall St.

    Is Innovent Biologics (HKG:1801) Weighed On By Its Debt Load?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

  • PR Newswire

    Innovent Biologics Study Results of IBI303 in Patients with Ankylosing Spondylitis was Published in "The Lancet Rheumatology"

    SUZHOU, China, Aug. 30, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX:01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines, today announced that the clinical trial results of IBI303, an anti-tumor necrosis factor-alpha (anti-TNF-alpha) monoclonal antibody injection developed by Innovent, has been published in The Lancet Rheumatology, a leading international medical journal, with comment by Stanley Cohen, professor of University of Texas Southwestern Medical Center.

  • PR Newswire

    Innovent Reports Interim Results for Fiscal Year 2019

    Strong Launch of First Commercialized Product, Transformative Progress in Pipeline Expansion and Drug Development SUZHOU, China , Aug. 29, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: ...